Shuji Asai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuji Asai has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Kenya Terabe
Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
24 shared publicationsToshihisa Kojima
Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Centre, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan
21 shared publicationsShiro Imagama
Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
19 shared publicationsNaoki Ishiguro
Aichi Developmental Disability Center, Kasugai, Japan
18 shared publicationsNobunori Takahashi
Department of Orthopaedic Surgery, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan
18 shared publications- Mochihito Suzuki
Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Nagoya Japan
17 shared publications
Latest Publications
- 15 November 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (11)
Clinical Characteristics of Sarcopenia Among SARC ‐F‐Negative Patients With Rheumatoid Arthritis
Background: Sarcopenia is clinically important in patients with rheumatoid arthritis (RA) because chronic inflammation and physical dysfunction may contribute to muscle impairment. Although SARC‐F is widely used as a screening tool for sarcopenia, its diagnostic performance in patients with RA remains unclear. This study investigated the agreement between SARC‐F and Asian Working Group for Sarcopenia 2025 (AWGS2025)‐defined sarcopenia and evaluated clinical characteristics of sarcopenia in SARC‐F‐negative patients with RA. Methods: This cross‐sectional study included 212 patients with RA enrolled in a prospective cohort. Sarcopenia was diagnosed according to the AWGS2025 criteria. Agreement between SARC‐F and AWGS2025‐defined sarcopenia was assessed using sensitivity, specificity, overall agreement, and Cohen's kappa coefficient. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed for SARC‐F‐negative patients. Results: The prevalence of SARC‐F positivity was 10.8%, whereas AWGS2025‐defined sarcopenia was observed in 25.0% of patients. Overall agreement between SARC‐F and AWGS2025‐defined sarcopenia was 72.6%, and Cohen's kappa coefficient was 0.10. Among SARC‐F‐negative patients, 23.3% had sarcopenia. Multivariable logistic regression analysis demonstrated that age and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) were independently associated with sarcopenia. ROC analysis identified an optimal HAQ‐DI cutoff value of 0.25. Patients with sarcopenia showed lower walking speed and prolonged Timed Up and Go performance, despite negative SARC‐F results. Conclusions: Among SARC‐F‐negative patients with RA, a substantial proportion met the AWGS2025 diagnostic criteria for sarcopenia and showed impaired physical performance. These findings indicate that a negative SARC‐F case‐finding result does not necessarily preclude sarcopenia diagnosed according to the AWGS2025 criteria. Trial Registration: UMIN Clinical Trials Registry: UMIN000041034
- 15 November 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (11)
Clinical Characteristics of Sarcopenia Among SARC ‐F‐Negative Patients With Rheumatoid Arthritis
Background: Sarcopenia is clinically important in patients with rheumatoid arthritis (RA) because chronic inflammation and physical dysfunction may contribute to muscle impairment. Although SARC‐F is widely used as a screening tool for sarcopenia, its diagnostic performance in patients with RA remains unclear. This study investigated the agreement between SARC‐F and Asian Working Group for Sarcopenia 2025 (AWGS2025)‐defined sarcopenia and evaluated clinical characteristics of sarcopenia in SARC‐F‐negative patients with RA. Methods: This cross‐sectional study included 212 patients with RA enrolled in a prospective cohort. Sarcopenia was diagnosed according to the AWGS2025 criteria. Agreement between SARC‐F and AWGS2025‐defined sarcopenia was assessed using sensitivity, specificity, overall agreement, and Cohen's kappa coefficient. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed for SARC‐F‐negative patients. Results: The prevalence of SARC‐F positivity was 10.8%, whereas AWGS2025‐defined sarcopenia was observed in 25.0% of patients. Overall agreement between SARC‐F and AWGS2025‐defined sarcopenia was 72.6%, and Cohen's kappa coefficient was 0.10. Among SARC‐F‐negative patients, 23.3% had sarcopenia. Multivariable logistic regression analysis demonstrated that age and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) were independently associated with sarcopenia. ROC analysis identified an optimal HAQ‐DI cutoff value of 0.25. Patients with sarcopenia showed lower walking speed and prolonged Timed Up and Go performance, despite negative SARC‐F results. Conclusions: Among SARC‐F‐negative patients with RA, a substantial proportion met the AWGS2025 diagnostic criteria for sarcopenia and showed impaired physical performance. These findings indicate that a negative SARC‐F case‐finding result does not necessarily preclude sarcopenia diagnosed according to the AWGS2025 criteria. Trial Registration: UMIN Clinical Trials Registry: UMIN000041034
- 12 November 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (12) , 311
Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey
- 12 November 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (12) , 311
Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey
- 26 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Prevalence of and factors associated with radiographic sacroiliitis in Japanese patients with inflammatory bowel disease: a computed tomography–based study
Objective: To determine the prevalence of radiographic sacroiliitis—a classification feature of spondyloarthritis—and to identify associated factors in Japanese patients with inflammatory bowel disease. Methods: This retrospective study included 880 patients with ulcerative colitis or Crohn’s disease who underwent abdominopelvic computed tomography at an inflammatory bowel disease centre. Sacroiliac joints were evaluated using a validated scoring system. Radiographic sacroiliitis was defined as a total erosion score ≥3 or the presence of sacroiliac joint ankylosis. Multivariate logistic regression analysis identified factors associated with radiographic sacroiliitis. Results: Radiographic sacroiliitis was identified in 98 patients (11%), including 41 patients (5%) with complete ankylosis. Crohn’s disease (vs. ulcerative colitis; odds ratio [OR] 2.14; 95% confidence interval [CI], 1.17–3.89), male sex (OR 3.85; 95% CI 1.96–7.56), and older age (OR 1.07 per year; 95% CI 1.05–1.09) were independently associated with radiographic sacroiliitis. In subgroup analysis, obesity was associated with radiographic sacroiliitis in Crohn’s disease (OR 2.15; 95% CI 1.01–4.59). Conclusions: Radiographic sacroiliitis was present in approximately 10% of Japanese patients with inflammatory bowel disease. Evaluation of sacroiliac joints on routine abdominopelvic computed tomography may help identify patients warranting further evaluation for coexisting spondyloarthritis, particularly in older men with Crohn’s disease.
- 26 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Prevalence of and factors associated with radiographic sacroiliitis in Japanese patients with inflammatory bowel disease: a computed tomography–based study
Objective: To determine the prevalence of radiographic sacroiliitis—a classification feature of spondyloarthritis—and to identify associated factors in Japanese patients with inflammatory bowel disease. Methods: This retrospective study included 880 patients with ulcerative colitis or Crohn’s disease who underwent abdominopelvic computed tomography at an inflammatory bowel disease centre. Sacroiliac joints were evaluated using a validated scoring system. Radiographic sacroiliitis was defined as a total erosion score ≥3 or the presence of sacroiliac joint ankylosis. Multivariate logistic regression analysis identified factors associated with radiographic sacroiliitis. Results: Radiographic sacroiliitis was identified in 98 patients (11%), including 41 patients (5%) with complete ankylosis. Crohn’s disease (vs. ulcerative colitis; odds ratio [OR] 2.14; 95% confidence interval [CI], 1.17–3.89), male sex (OR 3.85; 95% CI 1.96–7.56), and older age (OR 1.07 per year; 95% CI 1.05–1.09) were independently associated with radiographic sacroiliitis. In subgroup analysis, obesity was associated with radiographic sacroiliitis in Crohn’s disease (OR 2.15; 95% CI 1.01–4.59). Conclusions: Radiographic sacroiliitis was present in approximately 10% of Japanese patients with inflammatory bowel disease. Evaluation of sacroiliac joints on routine abdominopelvic computed tomography may help identify patients warranting further evaluation for coexisting spondyloarthritis, particularly in older men with Crohn’s disease.
- 4 May 2026
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
Factors associated with the recovery of physical function in patients with rheumatoid arthritis and locomotive syndrome: results from the Tsurumai–Frailty and Locomotive Syndrome of Rheumatoid Arthritis for Globalization study
- 4 May 2026
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
Factors associated with the recovery of physical function in patients with rheumatoid arthritis and locomotive syndrome: results from the Tsurumai–Frailty and Locomotive Syndrome of Rheumatoid Arthritis for Globalization study
- 2 November 2025
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 141, 106073
Nutritional status and frailty in rheumatoid arthritis: A multicenter observational study (T-FLAG)
- 2 November 2025
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 141, 106073
Nutritional status and frailty in rheumatoid arthritis: A multicenter observational study (T-FLAG)
- 6 September 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (1) , 105961
Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis
- 6 September 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (1) , 105961
Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis
- Open Access
- 8 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (1) , 25-31
The impact of social frailty and physical function on laughter frequency in rheumatoid arthritis patients: data from a multicenter observational study (Tsurumai-frailty and locomotive syndrome of rheumatoid arthritis for globalization)
Objectives: This study aimed to evaluate the relationship between laughter frequency, disease activity, physical function, and frailty in rheumatoid arthritis (RA) patients. Methods: A total of 679 consecutive RA patients from a multicenter observational study conducted in 2023 were included. Laughter frequency was assessed using a standardized questionnaire, and patients were divided into the following four laughter frequency groups: ‘almost every day’, ‘1–5 days per week’, ‘1–3 days per month’, and ‘never or almost never’. Patient characteristics for each frequency group were compared by analysis of variance. Multivariable logistic regression analyses were conducted to identify factors associated with frequent laughter. Results: Laughter frequency was ‘almost every day’ in 48.6% of patients, ‘1–5 days per week’ in 34.7%, ‘1–3 days per month’ in 9.9%, and ‘almost never’ in 6.8%. Laughter frequency was significantly associated with the Health Assessment Questionnaire-Disability Index (HAQ-DI) and social frailty. However, no significant correlation was observed between laughter frequency and disease activity. Patients with social frailty laughed less frequently than those without, and higher HAQ-DI scores were associated with less frequent laughter. Conclusions: Laughter frequency in RA patients is more strongly influenced by physical function and social frailty than by disease activity.
- 8 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (1) , 25-31
Open AccessThe impact of social frailty and physical function on laughter frequency in rheumatoid arthritis patients: data from a multicenter observational study (Tsurumai-frailty and locomotive syndrome of rheumatoid arthritis for globalization)
Objectives: This study aimed to evaluate the relationship between laughter frequency, disease activity, physical function, and frailty in rheumatoid arthritis (RA) patients. Methods: A total of 679 consecutive RA patients from a multicenter observational study conducted in 2023 were included. Laughter frequency was assessed using a standardized questionnaire, and patients were divided into the following four laughter frequency groups: ‘almost every day’, ‘1–5 days per week’, ‘1–3 days per month’, and ‘never or almost never’. Patient characteristics for each frequency group were compared by analysis of variance. Multivariable logistic regression analyses were conducted to identify factors associated with frequent laughter. Results: Laughter frequency was ‘almost every day’ in 48.6% of patients, ‘1–5 days per week’ in 34.7%, ‘1–3 days per month’ in 9.9%, and ‘almost never’ in 6.8%. Laughter frequency was significantly associated with the Health Assessment Questionnaire-Disability Index (HAQ-DI) and social frailty. However, no significant correlation was observed between laughter frequency and disease activity. Patients with social frailty laughed less frequently than those without, and higher HAQ-DI scores were associated with less frequent laughter. Conclusions: Laughter frequency in RA patients is more strongly influenced by physical function and social frailty than by disease activity.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial. A total of 112 participants aged 75–90 years were randomized equally into the romosozumab and denosumab groups. Among these, 49 and 52 participants, respectively, who received their initial dose were included in the analysis. The primary outcome was change in lumbar spine (LS)-bone mineral density (BMD) at 12 months in the romosozumab group versus the denosumab group. Secondary outcomes were changes in knee osteophyte development, patient-reported outcomes (PROs), and the incidence of serious adverse events. Mean age of participants was 80.9 years. There was no difference in baseline LS-BMD between the two groups, with a T-score of -2.6. The mean percentage change in LS-BMD at 12 months was significantly higher in the romosozumab group (13.7%) than in the denosumab group (8.5%; p = 0.0035). No significant differences were observed in knee osteophyte development and PROs between the two groups. Serious adverse events included a case of mitral regurgitation in the romosozumab group. These findings emphasize the need for refined treatment strategies in high-risk populations, highlighting romosozumab’s benefits and the need to monitor cardiovascular risks.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessA randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial. A total of 112 participants aged 75–90 years were randomized equally into the romosozumab and denosumab groups. Among these, 49 and 52 participants, respectively, who received their initial dose were included in the analysis. The primary outcome was change in lumbar spine (LS)-bone mineral density (BMD) at 12 months in the romosozumab group versus the denosumab group. Secondary outcomes were changes in knee osteophyte development, patient-reported outcomes (PROs), and the incidence of serious adverse events. Mean age of participants was 80.9 years. There was no difference in baseline LS-BMD between the two groups, with a T-score of -2.6. The mean percentage change in LS-BMD at 12 months was significantly higher in the romosozumab group (13.7%) than in the denosumab group (8.5%; p = 0.0035). No significant differences were observed in knee osteophyte development and PROs between the two groups. Serious adverse events included a case of mitral regurgitation in the romosozumab group. These findings emphasize the need for refined treatment strategies in high-risk populations, highlighting romosozumab’s benefits and the need to monitor cardiovascular risks.
- 15 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70288
Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis
Aim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test for between‐group comparisons. Differences in Clinical Disease Activity Index (CDAI) score from baseline were assessed using paired t‐tests, and generalized estimating equations were used to compare the treatment groups.Results: Baseline characteristics were similar between the baricitinib and filgotinib groups. Drug retention rates due to ineffectiveness or adverse events did not differ significantly between the two groups. In the baricitinib group, the estimated mean CDAI score significantly decreased from 17.8 at baseline to 9.1 at 4 weeks, 6.6 at 12 weeks, and 6.3 at 24 weeks (p < 0.001 for all comparisons). In the filgotinib group, the estimated mean CDAI score significantly decreased from 16.5 at baseline to 7.8 at 4 weeks, 6.2 at 12 weeks, and 6.1 at 24 weeks (p < 0.001 for all comparisons). No significant differences were observed between the two groups in CDAI score at any time point evaluated, or in the proportion of patients who achieved CDAI remission (CDAI ≤ 2.8) at baseline (7% vs. 5%) and after 4 (23% vs. 21%), 12 (33% vs. 33%), and 24 weeks (33% vs. 37%).Conclusion: Baricitinib and filgotinib demonstrated comparable drug retention rates and effectiveness in reducing disease activity among patients with RA over a 24‐week follow‐up period.
- 15 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70288
Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis
Aim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test for between‐group comparisons. Differences in Clinical Disease Activity Index (CDAI) score from baseline were assessed using paired t‐tests, and generalized estimating equations were used to compare the treatment groups.Results: Baseline characteristics were similar between the baricitinib and filgotinib groups. Drug retention rates due to ineffectiveness or adverse events did not differ significantly between the two groups. In the baricitinib group, the estimated mean CDAI score significantly decreased from 17.8 at baseline to 9.1 at 4 weeks, 6.6 at 12 weeks, and 6.3 at 24 weeks (p < 0.001 for all comparisons). In the filgotinib group, the estimated mean CDAI score significantly decreased from 16.5 at baseline to 7.8 at 4 weeks, 6.2 at 12 weeks, and 6.1 at 24 weeks (p < 0.001 for all comparisons). No significant differences were observed between the two groups in CDAI score at any time point evaluated, or in the proportion of patients who achieved CDAI remission (CDAI ≤ 2.8) at baseline (7% vs. 5%) and after 4 (23% vs. 21%), 12 (33% vs. 33%), and 24 weeks (33% vs. 37%).Conclusion: Baricitinib and filgotinib demonstrated comparable drug retention rates and effectiveness in reducing disease activity among patients with RA over a 24‐week follow‐up period.